Reducing the likelihood of skin cancer in an individual human being
View Patent ↗Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome.
1. A method of reducing the likelihood of skin cancer in an individual human being, said method comprising:
administering a therapeutically effective amount of a bacterial formulation comprising ammonia oxidizing bacteria selected from the group consisting of Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio , and Nitrosomonas eutropha , said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto at least a nasal region of an individual's skin wherein at least some bacteria in the bacterial formulation have been modified by using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to remove a virulence factor of the at least some bacteria.
2. The method as set forth in claim 1 , wherein the bacterial formulation further includes Propionibacterium bacteria.
3. The method as set forth in claim 1 , further comprising administering to the skin an extract derived from a helminth selected from the group consisting of Capillaria hepatica, Dicrocoelium dendriticum, Ascaris lumbricoides, Enterobius vermicularis, Trichuris trichiura, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Haemonchus contortus , and Trichinella spiralis.
4. The method as set forth in claim 1 , wherein the bacterial formulation includes at least one arabinogalactan.
5. The method as set forth in claim 1 , further comprising administering to the individual human being an immune checkpoint inhibitor.
6. The method as set forth in claim 1 , wherein the bacterial formulation comprises a topical lotion that comprises at least one of Lactobacillus johnsonii , and Bifidobacterium lognum bacteria.
7. The method as set forth in claim 6 , wherein the topical lotion is administered to an individual's skin as a probiotic bacteriotherapy to treat skin diseases selected from the group consisting of eczema, atopic dermatitis, acne, allergic inflammation, and skin hypersensitivity.
8. The method as set forth in claim 6 , wherein the topical lotion is administered to an individual's skin as a probiotic bacteriotherapy to treat ultra-violet-induced skin damage.
9. The method as set forth in claim 1 , wherein the bacterial formulation comprises proteins produced by said bacterial formulation.
10. The method as set forth in claim 1 , wherein the bacterial formulation enhances protection of skin from harmful ultra-violet radiation.
11. The method as set forth in claim 1 , wherein the bacterial formulation comprises a bifidobacterium strain.
12. A method of reducing the likelihood of skin cancer in an individual human being, said method comprising: administering a therapeutically effective amount of a bacterial formulation comprising ammonia oxidizing bacteria selected from the group consisting of Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio , and Nitrosomonas eutropha , said bacterial formulation including a bifidobacterium strain modified by using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to remove a virulence factor.
13. The method as set forth in claim 12 , wherein the bacterial formulation further includes Propionibacterium bacteria.
14. A method of reducing the likelihood of skin cancer in an individual human being, said method comprising: administering a therapeutically effective amount of a bacterial formulation comprising ammonia oxidizing bacteria selected from the group consisting of Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio , and Nitrosomonas eutropha , said bacterial formulation comprising Propionibacterium bacteria, wherein the Propionibacterium bacteria is modified by using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to remove a virulence factor.
15. The method as set forth in claim 14 , wherein the bacterial formulation is administered to an individual's skin as a probiotic bacteriotherapy to treat skin diseases selected from the group consisting of eczema, atopic dermatitis, acne, allergic inflammation, and skin hypersensitivity.
16. The method as set forth in claim 14 , further comprising administering to the skin an extract derived from a helminth selected from the group consisting of Capillaria hepatica, Dicrocoelium dendriticum, Ascaris lumbricoides, Enterobius vermicularis, Trichuris trichiura, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Haemonchus contortus , and Trichinella spiralis.
17. The method as set forth in claim 14 , wherein the bacterial formulation comprises a topical lotion that comprises at least one of Lactobacillus johnsonii , and Bifidobacterium lognum bacteria.
18. The method as set forth in claim 14 , wherein the bacterial formulation includes at least one arabinogalactan.
19. A method of reducing the likelihood of skin cancer in an individual human being, said method comprising: administering a therapeutically effective amount of a bacterial formulation comprising ammonia oxidizing bacteria selected from the group consisting of Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio , and Nitrosomonas eutropha , said bacterial formulation comprising Propionibacterium bacteria, wherein the Propionibacterium bacteria is modified by using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to remove a virulence factor, and administering to the individual human being an immune checkpoint inhibitor.
20. The method as set forth in claim 19 , wherein the immune checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.